Research and Practice in Thrombosis and Haemostasis

Article	Citations
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach	100
How to use and report data on D‐dimer testing in the COVID‐19 era?	93
PB0815 Involvement of the Nuclear Protein, TC2N, in Regulating VWF Levels in Endothelial Cells	79
PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing	73
OC 61.3 CS585 is a Novel and Highly Selective IP Receptor Agonist for Prevention of Thrombosis	58
PB1385 Developing a Stem Cell-Based Model for Glanzmann Thrombasthenia to Explore VWF-GPIb Axis during Megakaryopoeisis	53
OC 71.4 Management Patterns of Antithrombotics and Outcomes in Patients with Hematological Malignancy and Thrombocytopenia: A Prospective Registry (Matter Study)	47
OC 03.2 Characterization of Peripheral Monocyte Subsets in a Prospective Cohort of Patients with Acute Stroke Suspicion: Results of BOOST Study	45
OC 42.5 Hemorrhagic Risk of Caplacizumab in the Treatment of Thrombotic Thrombocytopenic Purpura a Pharmacovigilance Study from 2020–2022 FAERS Database	42
PB0046 Increased Platelet Activation Demonstrated by Elevated CD36 and P-Selectin Expression in 1-year Post Recovered COVID-19 Patients	41
OC 53.5 Clinical Outcomes in Patients with Acute Pulmonary Embolism Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis	39
PB0074 Hyper-Immunoglobulin-CovImmuneTM, Provides a Broader Coverage Against Diverse SARS-CoV-2 Variants Relevant to the COVID-19 Pandemic	39
PB0957 The Application of Existing Risk Assessment Models (RAMs) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin's Lymphoma	39
PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec	36
PB1463 Clinical Predictors of In-Hospital Mortality in Patients with Acute Pulmonary Embolism: 15-Years Experience in a Single Center in Argentina	36
PB0464 Smaller Nadroparin Dose Reductions Required for Patients with Renal Impairment: A Multicenter Study	34
PB1031 Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC: KVAD Study	34
PB0926 Venous Thromboembolism and Risk of Depression in Patients with Hematological Cancer: A Population-Based Cohort Study	33
OC 74.1 Circulating Biomarkers and Mortality in Atrial Fibrillation: The Reasons for Geographic and Racial Differences in Stroke Study	32
PB1228 Inhibitor Detection in Acquired Hemophilia A: A Comparison between the Nijmegen Modified Bethesda Assay and an Anti-FVIII ELISA	31
PB0386 Increased Platelet Expression of the Transcriptional Suppressor ETV6 Can Be Detected by Immunofluorescence on the Blood Smear and Associates with ETV6-Related Thrombocytopenia	31
OC 45.3 Major Bleeding Event Rates in Patients on Hemodialysis and Peritoneal Dialysis: Results from the International DOPPS and PDOPPS	29
PB1020 Simultaneous Generation of Thrombin and Plasmin in Patients with Deep Vein Thrombosis and High Levels of Lipoprotein (a)	29
PO16 Hemorrhagic Complications in Patients with Hemophilia A	28
PB0612 COVID-19: Predictive Value of Methemoglobinemia	28

OC 71.5 Reasons for Anticoagulation Failure and Provider Management	28
PB0715 H3 Alters the Behavior of Endothelial Cells In Vitro	28
OC 75.1 First US Rare Bleeding Disorder Genotype-Phenotype Registry (ATHN 10) Discovers Many Individuals with Both Novel and Multiple Variants using a Customized 30-Gene Next-Generation Sequencing Pan	27
PB1142 A Rapid Centrifugation 4000 g, 4 min Does not Impact Routine Coagulation Assays	27
PB0358 Hereditary Bleeding Disorders Web-Based Registry of Patients with Inherited Platelet Disorders	26
PB0412 Simulating the Impact of Thrombin on Platelet Function Requires Simultaneous Activation of Both PAR-1 and PAR-4	26
PO04 SARS-CoV-2 Vaccinations and Risk of Venous Thrombosis - Case Control Study	25
PB1060 Thrombin Generation and Fibrin Clot Structure in Nephrotic Patients with Primary Glomerular Disorders	25
PB1140 Laboratory Features and Genotype of a Family with Heritable Dysfibrinogenaemia (HD)	24
PB0679 Clinical Characteristics and Disease Outcomes in Previously Treated Patients with Haemophilia: Results from a Real-World Study in Europe and United States	24
PB0299 Surface Modification of Lung Assist Device for Neonates by Dual-Modification with Antithrombin-Heparin (ATH) and Tissue Plasminogen Activator (t-PA)	24
PB0403 A Common Variant in GRK5 Reveals a PAR1-Specific Regulation in Platelets	24
OC 50.1 Levels of IgG4 Distinguish Immune Tolerance Induction Outcome in Patients with Inherited Hemophilia A: Results from the BrazIT Study	23
Issue Information	23
PB0308 Anticoagulation Monitoring of UFH (Unfractioned Heparin) in a Pediatric Patient during Long Term ECMO (Extracorporeal Membrane Oxygenation)	22
PB0627 Management of Invasive Procedures in Patients with Hemophilia A Receiving Emicizumab Prophylaxis: Real-World Data from a National Hemophilia Treatment Center	22
Impact of antiplatelet therapy on hemostatic plug formation in the setting of thrombocytopenia	21
HTRS2025.O8A.6 The heme-induced mitochondrial oxidant-dependent platelet secretome promotes endothelial dysfunction	21
PB0249 Some Coagulation Profiles (PT, APTT, TT, FIB), Red Cell, Total White Cell, Platelet Counts and Their Indices Activity Levels in Persons Exposed to Wood Smoke (Firewood) in Calabar, Nigeria	21
HTRS2025.P1.29 Factors Associated with Disseminated Intravascular Coagulation in non-APL Acute Myeloid Leukemia	21
PB0796 Interferon Treatment Suppresses in vitro NETosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms	21
141 Heparin Management - The Ultimate Goldilocks Dilemma: A Quality Improvement Project	20
HTRS2025.P1.8 Efanesoctocog Alfa for the Perioperative Management of Patients With Severe Hemophilia A: 4 Years of Experience in the XTEND Clinical Program in North America	20
128 Evaluation of Heparin-Induced Thrombocytopenia Testing to Improve Anticoagulation Stewardship in an Acute Care Setting	20
140 Impact of Amiodarone Exposure on Apixaban Pharmacokinetics in Hospitalized Patients	20
Erratum to ‘A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays.’ [Research and Practice in Thrombosis and Haemostasis Vo	19
Thrombophilia and outcomes of venous thromboembolism in older patients	19
Corrigendum to ‘Optimizing care for patients after major anticoagulant-related bleeding: a narrative review and proposal for a clinical care pathway’	19
84 Rural Improvements in Venous Thrombosis Treatment in Oklahoma: The RIVETT-OK Initiative	19
Contemporary trends in maternal outcomes during delivery hospitalizations among pregnancies complicated by von Willebrand disease—a cross-sectional analysis	19
Von Willebrand disease diagnosis: from complexity to simplicity	19
Emicizumab prophylaxis in current haemophilia A care in the Czech Republic—data from the Czech National Haemophilia Programme Registry	19
Exploration of biomarkers for inhibitor development in persons with hemophilia A	19
Accumulating evidence for direct oral anticoagulants in liver disease	18
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3	18
Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms	18
Acquired von Willebrand syndrome in children	18
Performance of risk scores in predicting major bleeding in left ventricular assist device recipients: a comparative external validation	18
The importance of data transformation in correlation analysis of factor VIII and inhibitor titers in acquired hemophilia	18
Intraindividual variability of von Willebrand factor and the need for repeated testing	18
Do combined oral contraceptives induce formation of tissue factor?	18
Safety and efficacy of direct oral anticoagulants in patients with liver cirrhosis: a meta-analysis	18
How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study	17
Promise and pitfalls of viscoelastic testing for assessing blood hemostasis in ultraendurance sports	17
OC 14.2 Pharmacokinetic Characteristics of ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Results from a Phase 3 Randomized, Controlled, Open-Label, Crossover Study	17
Rare inherited coagulation disorders: no longer orphan and neglected	17
Prognostic value of the pan-immune-inflammation value for mortality in sepsis-induced coagulopathy: a Medical Information Mart for Intensive Care study	17
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality	17
Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates	17
Cryo‐EM structures of coagulation factors	16

EP1T5_6 The impact of iron deficiency on hemodynamic status in patients with acute heart failure: a preliminary study via USCOM device	16
Heat treatment of emicizumab samples – a way forward?	16
Real-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding	16
High-throughput Image-based Matrix Analysis Platform Software: development of an algorithm for standardized characterization of high-resolution fibrin clot images	16
Navigating the inevitable: artificial intelligence and the future of scientific communication	16
Avatrombopag in Thrombopoietin Receptor Agonist Naïve Patients with Immune Thrombocytopenia: Real-World Treatment Patterns & Clinical Outcomes from the REAL-AVA 3.0 Study	16
Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients	15
PB1383 RUNX1-Mutated Familial Platelet Disorder (RUNX1-FPD) with Associated Acute Myeloid Leukaemia - A Case/Family Series	15
Editorial Board	15
EP1T3_5 Massive Transfusion Protocol (MTP) Activations at Hospital Shah Alam, Malaysia	15
Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China	15
Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus: A retrospective cohort study	15
Tissue factor-heparanase complex: intracellular nonhemostatic effects	15
PB0695 Comparison of Platelet Quality and Hemostatic Function Across Apheresis Collection Platforms	15
EP3T3_5 Minimal Invasive Surgery is the Key to PBM and ERAS	15
Analytical validity of the INNOVANCE Antithrombin assay for the measurement of antithrombin activity at fitusiran clinical decision points	15
The diagnostic utility of genetic testing in inherited thrombocytopenia: regional multicenter tertiary experience	15
HTRS2023.P2.3 F8 variants in women and girls evaluated for hemophilia A	15
OC 70.2 The First Insight into the Spatial Structure of Human Kininogen by Cryogenic Electron Microscopy and Computational Methods	15
EP1T6_4 Machine Learning based prediction of platelet concentration from ROTEM Measurements	15
Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany	15
Daratumumab in relapse-refractory immune-mediated thrombotic thrombocytopenic purpura: additional evidence for its efficacy	15
OC 72.5 Prediction of Venous Thromboembolism in Diverse Ancestry Populations Using Machine Learning and Electronic Health Records	14
PB1519 Analysis of Aggregation Patterns Changes in Pregnant Women with Severe Preeclampsia	14
PB1133 DaXa, a Non-Calibrated Anti-FXa Assay that can be Used to Quantify DOAC Concentration in Acute Medical Emergencies	14
Hematopoietic stem cell transplantation in a newborn suffering from severe combined immunodeficiency and severe hemophilia A: a case report and review of the literature	14
PB1146 Comparison of Three Warfarin Monitoring Tests (PT, P&P and Fiix test) in Anticoagulated and Non-Anticoagulated Lupus Anticoagulant Positive Plasma Samples	14
OC 54.2 Comparison of Direct Oral Anticoagulants versus Low Molecular Weight Heparin in Primary and Metastatic Brain Cancers: A Meta-Analysis and Systematic Review	14
PB1152 Reporting of DOAC Concentration as FXa Inhibitory Units - Potential Solution for Smaller Laboratories?	13
OC 77.1 Development, Validation, and Implementation of a Decision Support Tool for the Screening of Mild Bleeding Disorders	13
PB0311 Anticoagulation in a Hypercoagulable Infant with End-Stage Renal Disease on Renal Replacement Therapies	13
PB1433 Opposing Effects of Canonical and Non-Canonical PAR-1 Activation in Experimental Diet-Induced Obesity and Fatty Liver Disease	13
Stroke prevention in atrial fibrillation with chronic kidney disease: a delicate balance of efficacy and safety considerations	13
OC 60.1 Delineating VonWillebrand Factor Genetic Variants in Patients with a Von Willebrand Disease Diagnosis	13
PB0150 Fibrin Clot Formation is a Reliable Biological Marker to Evaluate FVIII Replacement Therapy in Hemophilia A Patients	13
PB0421 Phosphoproteomics and Systems Analysis Reveal Protein Kinase C Theta (PKCfɵ) Signaling Events Associated with the Generation of Procoagulant Platelets	13
Advanced practice provider–led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilization	13
PB1156 Clinical Performance Evaluation of the New Stago System for Fibrinogen and Thrombin Time Determination: sthemO Fib and sthemO Thrombin on sthemO 301 Analyzer	13
PB0979 Significantly Increased CVC Replacement in Patients with Both Symptomatic and Incidental Venous Thrombotic Events in Pediatric Cancer Patients: A Population-Based Study	13
OC 11.1 Development and Validation of a Clinical Prediction Model for the Diagnostic Management of Acute Pulmonary Embolism: An Individual Participant Data Meta-Analysis	12
OC 75.3 Phenotype and Genotype Characterization of Patients with Congenital Fibrinogen Deficiencies: A Retrospective Analysis of the PRO-RBDD Database	12
PB1427 Reduced ADAMTS13 Activity in Staphylococcus Aureus Bacteremia is Associated with Neutrophil-Mediated Citrullination	12
PB0005 The Interest of the Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in the Prediction of Thrombus in Myocardial Infarction	12
PB0380 Corrections of Bernard Soulier Syndrome Megakaryocyte Phenotypes by Small Molecules and Interleukin-1α	12
PB1466 Early Mortality in Pulmonary Embolism - A Systematic Review and Analysis	12
PB0706 Mechanism by which Coagulation Factor XI Regulates Endothelial Cell Permeability and Barrier Function In Vitro and In Vivo	12
OC 22.1 Proteome and Phosphoproteome Analyses of SARS-CoV-2 Infected Humanized ACE2 Mice Platelets Revealed Reprogramming of Platelets from Early Hyperreactive to Late Antiviral Phenotypes	12
OC 03.4 A Common, Racially Diverse Protease Activated Receptor 4 Functional Variant Impacts Ischemic Stroke Outcomes: Evidence for a Pharmacogenetic Effect	12
PB0437 Concordance of Phosphatidylserine/Prothrombin and APhL Antibodies Associated with Antiphospholipid Syndrome-Associated Pregnancy Morbidity	12
PB0117 COVID-Associated Thrombosis: New Insights	12
PB1072 A Novel Factor VIII Specific APC Resistance Assay	12
PB0723 Protease-Activated Receptor 4 Differentially Modulates TLR3- Dependent Responses In Vitro and In Vivo	12
PB1193 Acute Myocardial Infarction Thrombi Show Fibrin Film that Increases with Ischaemia Duration	12
PO19 Clinical Experiences in Managing the Transition to rIX-FP: Switching, Surgical Management and On-Demand	12
PB0448 Fibrin Clot Properties Identify Patients that Benefit from Catheter- Directed Thrombolysis: A Post Hoc Analysis of the CAVA Trial	12
PB1210 Incorporation of a2-Plasmin Inhibitor into Plasma Clots of Patients with Venous Thrombosis	11
Estimating incidence of venous thromboembolism in COVID‐19: Methodological considerations	11
PB1377 Living with Glanzmann's Thrombasthenia: An Interim Report from the Glanzmann's 360 International Patient Survey	11
Galectin-3-binding protein and future venous thromboembolism	11
HTRS2023.P2.16 Prevalence of iron deficiency in patients with inherited bleeding disorders	11
Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study	11
PO26 Pulmonary Embolism in a Case with Thrombotic Thrombocytopenic Purpura after Plasmapheresis	11
PB1176 Analytical Performances Evaluation of the sthemO VWF:Ag Assay on the sthemO 301 Analyzer	11
Effect of plasma levels of factor VIII according to procoagulant phospholipids on the risk of future venous thromboembolism	11
SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people	11
Regulation of megakaryo/thrombopoiesis by endosomal toll-like receptor 7 and 8 activation of CD34+ cells in a viral infection model	11
Exploring heterogeneity in reported venous thromboembolism risk in COVID-19 and comparison to other viral pneumonias: a systematic review and meta-regression	11
PB1013 Evaluation of the Diagnostic Performance of Three D-Dimer Assays in Patients with Suspected Deep Vein Thrombosis	11
Relevance of anti–platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic	11
HTRS2025.O6B.2 Abstract Travel Award Platelet RIG-I promotes Flu-Induced Severe Lung Injury in Sickle Cell Disease	11
Excluding pregnancy-associated deep vein thrombosis with whole-leg ultrasound	11
Managing surgical relapse risk in acquired thrombotic thrombocytopenic purpura: a systematic review	11
Arthropathy on X-rays in 363 persons with hemophilia: long-term development, and impact of birth cohort and inhibitor status	11
Quality of life and functional recovery after venous stent placement for postthrombotic syndrome: insights from the ARIVA multinational randomized trial	10
Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study	10
Changes in body mass index following venous thromboembolism in children: a prospective cohort study	10
D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap	10
Joint tissue plasticity in hemophilia: insights from the Joint Activity and Damage Exam ultrasound protocol	10
Coagulation activation in anorexia nervosa: increased tissue factor and prothrombin fragment 1+2	10
How I respond to peer reviewer comments	10

Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE	10
Coagulation Potential of Concomitant Factor VIII Administration in People with Hemophilia A Receiving Emicizumab Prophylaxis (CAGUYAMA Study): A Multicenter, Open-Label, Non-Randomized Clinical Trial	10
Neuraxial analgesia in pregnant individuals with bleeding disorders: a retrospective descriptive study of obstetric anesthesia practices and outcomes	10
Thrombin Generation Parameters Provide Independent Information on Plasma Coagulation Potential in Pediatric Patients on Extracorporeal Membrane Oxygenation: a Prospective Single-Center Pilot Study	10
Comparison of different algorithms for lupus anticoagulant detection: a single-center experience	10
Venous thromboembolism following surgery for pancreatic neuroendocrine neoplasms	10
Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay	10
Factor V variants in bleeding and thrombosis	10
Tranexamic acid for management of heavy vaginal bleeding: barriers to access and myths surrounding its use	10
Thrombin generation and implications for hemophilia therapies: A narrative review	10
Probing rare von Willebrand disease–causing mutations in the D4 and C-domains of von Willebrand factor	10
Bedside exclusion of pulmonary embolism in children without radiation (BEEPER): a national study of the Pediatric Emergency Care Applied Research Network—Study protocol	10
Heparin-induced thrombocytopenia in patients with mechanical circulatory support: A systematic review and meta-analysis.	10
Lower early mortality and risk prediction improvement of obesity after acute pulmonary embolism: results from a multicenter cohort analysis with external validation	10
Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center	10
Interference of lupus anticoagulant causing antiprothrombin and anti–beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized r	10
Major bleeding and thromboembolism risks of antithrombotic treatment in patients with incident atrial fibrillation/flutter and a history of cancer	10
132 Antithrombotic Prescribing Practices in Patients with Atrial Fibrillation Presenting with Acute Ischemic Stroke while on Oral Anticoagulation	10
Extracellular vesicle tissue factor and tissue factor pathway inhibitor are independent discriminators of sepsis-induced coagulopathy	10
High-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal Before Urgent Surgery: Sub-Analysis of the LEX-209 Randomized, Active-Controlled Trial	10
PB0708 The Tissue Factor/Thrombin Axis Limits Spontaneous Lymphatic Metastasis in Mice	9
PB1527 Sticky Platelet Syndrome and Pregnancy Complications - 18 Years' Experience in National Center of Hemostasis and Thrombosis in Slovak Republic	9
Extravascular distribution of factor IX – review of experimental and clinical evidence, and relevance for hemophilia B replacement therapy	9
PB0644 Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study	9
PB1424 PCF11 is a Central Hub in the Regulation of Inflammation in an Animal Model of Septicemia	9
PO08 Factor XIII Deficiency as Underlying Cause of Unexplained Intracranial Hemorrhage	9
PB0945 Effect of Drug Interactions with Apixaban on Clinical Outcomes in Cancer Patients with Venous Thromboembolism	9
PB0659 Patients with Hemophilia A have Increased Levels of Circulating Activated Protein C: Potential Contribution to their Hemostatic Status	9
PB0452 Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro- Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism	9
PB0865 Endothelial Extracellular Vesicles Regulate In Situ Pulmonary Thrombosis in Sickle Cell Disease	9
PB0141 Characterizing the Transcriptomic Profile of Acquired Hemophilia Using RNA-Seq	9
OC 63.3 Combined Effect of High Factor VIII Levels and High Mean Platelet Volume on the Risk of Future Venous Thromboembolism	9
PO34 The Risk of Vein Thromboembolism and Prevention in the Critically Illness Facilitated with an Electronic Decision Support System	9
PB0911 Platelet Reactivity in Patients with Atrial Fibrillation and Coronary Artery Disease under IIa Antagonists and Xa Antagonists	9
PB0319 Overexpression of ANKRD26 Results in Thrombocytopenia That May Exacerbate Clinical Phenotypes of Thrombotic Thrombocytopenic Purpura	9
PB0127 D-Dimer: Advantage Lost in the Post COVID Era?!	9
PB1517 Effect of Uteroplacental Manipulation on Hemostatic Markers during Cesarean Delivery and Hysterectomy for Placenta Accreta Spectrum	9
OC 35.3 Correlation between ETP-Based APC Resistance and the Relative Risk of Venous Thromboembolism in Women Using Combined Oral Contraceptives	9
OC 27.2 Mechanistic Studies of Runt-Related Transcription Factor-1 (RUNX1)-Deficient Megakaryopoiesis and its Correction by RepSox (RS), a TGFβ-Receptor-1 Inhibitor	9
PB0837 Analysis of the Change in Diagnosis of von Willebrand Disease by Region and Economic Status	9
PB0994 Intronic Exploration of PROC in Patients with Unexplained Protein C Deficiencies	9
PB1345 Health-Related Quality of Life Assessed by the SF-36 Health Survey in the Vienna ITP Biobank	9
Incidence rate of venous thrombosis in women switching combined oral contraceptives: a cohort study	9
PB1062 Exogenous Warfarin Intoxication Associated with Munchaüsen Syndrome	9
OC 60.5 Response to Desmopressin in Type 2N Von Willebrand’s Disease: A Genotype-Phenotype Analysis on a Cohort of 121 Patients	9
PB0315 Characterizing Protease-Resistant ADAMTS13 Mutants	9
OC 38.3 Effects of Apixaban Versus No Anticoagulation on Biomarkers of Thrombin Generation in Pediatric Acute Lymphoblastic Leukemia (ALL): A Biomarker Sub-Study of PREVAPIX-ALL, a Randomized Controll	9
PB1461 Peri-Operative Venous Thromboembolism (VTE) Risk for Below Knee Amputations	9
PB0233 Von Willebrand Disease in the East Mediterranean Region: Current Situation and Gaps	9
PB0633 Understanding the Requirement for Additional Factor VIII Infusion Associated with Novel Haemophilia A Treatments: An Expert Elicitation Exercise	8
PB0047 COVID-19 Infection-Associated Platelet and Neutrophil Activation is Blunted by Previous Anti-SARS-CoV-2 Vaccination	8
LB 01.4 Rare Germline Loss of Function Variants in SERPINH1 (HSP47) are Associated with Increased Risk of Thrombosis	8
PB1161 Evaluation of Three Prothrombin Time Reagents and their Sensitivity to Extrinsic Pathway Factor Deficiencies (FII, FV and FVII)	8
PB0545 The Effect of a History of Preeclampsia on Hemostatic Balance in the Non-Pregnant State	8
PB0699 Idarucizumab for Dabigatran Reversal: A Systematic Review and Meta-Analysis of Indications and Outcomes	8
OC 10.3 Platelets Mediate Intracranial Aneurysm Formation and Rupture in Mice	8
Issue Information	8
HTRS2023.O8B.3 Elucidating the molecular mechanism of excessive phosphatidylserine exposure in sickle red cells	8
PB0518 Novel Insights into Antifibrinolytic and Prothrombotic Functions of Lipoprotein(a)	8
PB0707 Neutrophil Extracellular Traps Promote Cancer-Associated Inflammation and Myocardial Stress	8
PB1520 Deep Learning Extracts Embedded Signatures Associated with Pregnancy and Preeclampsia from Circulating Vesicle Profiles	8
PB0910 Evaluation of the Clot Formation Tranfusing Fresh, Cold and Frozen Platelets. Advantages for the Military Environment	8
OC 50.2 Low Dose FVIII Injections as a Potential Treatment to Prevent Inhibitor Development in Hemophilia a - an in Vivo Study	8
PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Stud	8
HTRS2023.P4.20 Systematic review of global hemostasis assays in myeloproliferative neoplasms: promising tools for biomarkers for hypercoagulability	8
PB0908 Therapeutic Efficacy of Platelet-Rich Plasma in Chronic Compression of the Dorsal Root Ganglion in Rat	8
PB0153 Evaluation of Cell Type-Specificity of Native Enhancer Elements from the F8 Locus	8
PB0408 Regulation of Collagen Binding Integrins by Alpha 7 and C Helix	8
PB1027 Delayed Diagnosis and Treatment of Deep Vein Thrombosis-an Underrecognized Factor for Its Related Complications?	8
OC 42.2 Incidence and Risk Factors of Major Adverse Cardiovascular Events in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura during Remission	8
PB0812 The Importance of the Amino-Acid Residue at Position 2561 in the C4-Domain of von Willebrand Factor	8
PB1153 Shortening of APTT when Heparin Neutralising Calcium Solution Replaces Calcium Alone is Highly Specific for the Presence of Heparin	8
Patients with metabolic dysfunction–associated steatotic liver disease have preserved in vitro responses to antiplatelet drugs	8
PB1059 Single Amino Acid Substitutions of an Antibody Specific for a Non-Active Site of Activated Protein C (APC) Yielded an Antibody Library Capable of Modulating and Uncoupling APC Pleiotropic Funct	8
Predictors of diagnostic delays and loss to follow-up in women with von Willebrand disease: a single-center retrospective cohort study	7
Red blood cell–derived transglutaminase 2 influences thrombus formation	7
A novel mechanism underlying allosteric regulation of ADAMTS-13 revealed by hydrogen−deuterium exchange plus mass spectrometry	7
Extravascular factor IX after gene therapy in hemophilia B, does it matter?	7
Identification of novel PROS1 variants through systematic analysis of patients with suspected hereditary protein S deficiency	7
International collaborative study for the calibration of a proposed World Health Organization International Standard for thromboplastin, human, recombinant: a report from the International Federation	7
Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies	7
Hemophilia and hereditary angioedema: parallel therapeutic advances in genetic diseases of serine protease pathways	7
Comparing survival with vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants in patients with cancer—a systematic review and meta-analysis	7
131 Evaluation of Hemoglobin Monitoring Frequency in Patients on Anticoagulation Therapy	7
HTRS2025.P1.43 Resumption of Anticoagulant Therapy After Clinically Significant Bleeding in Patients with Cancer-associated Venous Thromboembolism	7
Comparison of monthly bleeding rates after direct oral anticoagulant initiation for venous thromboembolism and atrial fibrillation	7
HTRS2025.P2.63 Characterization of Pediatric Patients with Hemophilia and Obesity Followed by the University of North Carolina Hemophilia Treatment Center	7
Early SARS-CoV-2 infection: Platelet-neutrophil complexes and platelet function	7
The Evolution of Hemophilia Therapeutics: An Illustrated Review	7
Recombinant factor VIIa: new insights into the mechanism of action through product innovation	7
HTRS2025.P2.97 A mathematical modeling approach to understanding the lipid dependence of emicizumab	7
HTRS2025.P1.13 Characteristics and Clinical Outcomes of Thrombotic Thrombocytopenic Purpura in a Distinct Demographic	7
Therapeutic strategies in intracerebral hemorrhage: from hematoma stabilization to alleviating secondary brain injury	7
In vitro comparison of the effects of abelacimab, dalteparin, and apixaban on catheter-induced clotting and thrombin generation	7
A multicenter prospective observational cohort study to improve diagnostic yield and clinical management of persons with a Bleeding Disorder of Unknown Cause (BDUC-iN study protocol)	7